{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:57:01Z","timestamp":1791561421150,"version":"4.3.4"},"reference-count":0,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"abstract":"<jats:p>This Medical News article discusses the reasons behind the burgeoning black market for 2 unapproved GLP-1 weight loss drugs and the potential risks associated with their use.<\/jats:p>","DOI":"10.1001\/jama.2026.20514","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:30:17Z","timestamp":1791559817000},"source":"Crossref","is-referenced-by-count":0,"title":["Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain"],"prefix":"10.1001","author":[{"given":"Rita","family":"Rubin","sequence":"first","affiliation":[{"name":"Lead Senior Staff Writer, Medical News, JAMA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,9]]},"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2855339\/jama_rubin_2026_mn_260077_1791402537.52723.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:30:17Z","timestamp":1791559817000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2855339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1001\/jama.2026.20514","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,9]]}}}